• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

InGeneron inks collaboration with German Accelerator Life Sciences

December 5, 2016 By Sarah Faulkner

InGeneron inks collaboration with German Accelerator Life SciencesInGeneron said today that it landed a collaboration with the German Accelerator Life Sciences program, establishing an additional U.S. presence in Cambridge, Mass. The initiative is supported by the German Federal Ministry for Economic Affairs & Energy.

The GALS program will provide InGeneron with a group of mentors to help leverage its network within the industry and support the company’s U.S. presence and development in Europe. GALS will continue to support InGeneron as the company launches clinical development in the U.S. and expands its distribution network, the program said.

Houston, Texas-based InGeneron develops regenerative cell therapies for orthopedic and wound healing indications.

“Our new presence in Cambridge will help us access one of the world’s leading life sciences and biotechnology hubs and tap into the local talent pool,” InGeneron CEO Michael Coleman said in prepared remarks. “Additionally, being accepted into the GALS program is a commendation for our teams on both sides of the Atlantic. The broad network and expertise of GALS represents a significant opportunity for the company.”

“We are excited to start our collaboration with InGeneron. The company’s adipose-derived regenerative cell-based technology has great potential across several indications. We are confident that GALS can add significant value and help InGeneron establish its innovative approach in the US and Europe,” GALS CEO Christoph Lengauer added.

Filed Under: Orthopedics, Regenerative Medicine, Stem Cells, Wall Street Beat, Wound Care Tagged With: German Accelerator Life Sciences, InGeneron

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS